Is the Use of ACE Inhibitors Prior
to the Onset of Scleroderma Renal Crisis Associated with Worse
Outcome?
Coordinating center: SMBD-Jewish General Hospital, Montreal,
Canada
Other centers:Canadian Scleroderma Research Group,
Scleroderma Clinical Trials Consortium, EUSTAR
Design: Cohort
Inclusion criteria: Subjects will be all scleroderma patients
diagnosed with scleroderma renal crisis by a participating
rheumatologist during a 52-week period.
Exclusion criteria: None
Primary outcome measure: Death or dialysis one year after the
onset of SRC in those exposed compared to those not exposed to ACE
inhibitors at the onset of the scleroderma renal crisis.
Secondary outcome measures: Death or dialysis, assessed
seperately, during the first year after SRC; renal function at one
year.
Recruitment period: 52 weeks
Completion: One-year follow up
Date of expected analysis: Fall 2010